4 false false false false false false false false false false true false false false false false false No description of principal activity 2024-07-01 Sage Accounts Production Advanced 2024 - FRS102_2024 6,944 6,944 xbrli:pure xbrli:shares iso4217:GBP 08697526 2024-07-01 2025-06-30 08697526 2025-06-30 08697526 2024-06-30 08697526 2023-07-01 2024-06-30 08697526 2024-06-30 08697526 2023-06-30 08697526 bus:Director3 2024-07-01 2025-06-30 08697526 core:WithinOneYear 2025-06-30 08697526 core:WithinOneYear 2024-06-30 08697526 core:ShareCapital 2025-06-30 08697526 core:ShareCapital 2024-06-30 08697526 core:SharePremium 2025-06-30 08697526 core:SharePremium 2024-06-30 08697526 core:RetainedEarningsAccumulatedLosses 2025-06-30 08697526 core:RetainedEarningsAccumulatedLosses 2024-06-30 08697526 bus:Director1 2024-07-01 2025-06-30 08697526 bus:SmallEntities 2024-07-01 2025-06-30 08697526 bus:AuditExemptWithAccountantsReport 2024-07-01 2025-06-30 08697526 bus:SmallCompaniesRegimeForAccounts 2024-07-01 2025-06-30 08697526 bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 08697526 bus:FullAccounts 2024-07-01 2025-06-30 08697526 core:OfficeEquipment 2024-07-01 2025-06-30 08697526 core:OfficeEquipment 2025-06-30
COMPANY REGISTRATION NUMBER: 08697526

Persica Pharmaceuticals Limited

Filleted Unaudited Financial Statements

30 June 2025

Persica Pharmaceuticals Limited

Financial Statements

Year ended 30 June 2025

Contents | Page

Statement of financial position | 1

Notes to the financial statements | 2

Persica Pharmaceuticals Limited

Statement of Financial Position

30 June 2025

| 2025 | 2024
Note | £ | £ | £

Current assets

Debtors | 6 | 102,014 |  | 92,181
Cash at bank and in hand | 2,393,388 |  | 2,183,748
| ------------ |  | ------------
| 2,495,402 |  | 2,275,929

Creditors: amounts falling due within one year | 7 | 396,147 |  | 324,615
| ------------ |  | ------------
Net current assets |  | 2,099,255 | 1,951,314
|  | ------------ | ------------
Total assets less current liabilities |  | 2,099,255 | 1,951,314
|  | ------------ | ------------
Net assets |  | 2,099,255 | 1,951,314
|  | ------------ | ------------

Capital and reserves

Called up share capital |  | 21,036 | 20,373
Share premium account |  | 21,576,948 | 18,427,596
Profit and loss account |  | ( 19,498,729) | ( 16,496,655)
|  | ------------- | -------------
Shareholders funds |  | 2,099,255 | 1,951,314
|  | ------------- | -------------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 15 October 2025 , and are signed on behalf of the board by:

Dr S Ruston
Director

Company registration number: 08697526

Persica Pharmaceuticals Limited

Notes to the Financial Statements

Year ended 30 June 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 7 Denne Hill Business Centre, Womenswold, Canterbury, Kent, CT4 6HD.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The accounts have been prepared on a going concern basis which relies upon the continuing support of the investors.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

| Equipment | - | 33% straight line

Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 4 (2024: 4 ).
5. Tangible assets

| Equipment | Total
| £ | £
Cost |  |
At 1 July 2024 and 30 June 2025 | 6,944 | 6,944
| ------- | -------
Depreciation |  |
At 1 July 2024 and 30 June 2025 | 6,944 | 6,944
| ------- | -------
Carrying amount |  |
At 30 June 2025 | – | –
| ------- | -------
At 30 June 2024 | – | –
| ------- | -------

6. Debtors

| 2025 | 2024
| £ | £
Other debtors | 102,014 | 92,181
| --------- | --------

7. Creditors: amounts falling due within one year

| 2025 | 2024
| £ | £
Trade creditors | 269,336 | 252,135
Social security and other taxes | 121,911 | 68,130
Other creditors | 4,900 | 4,350
| --------- | ---------
| 396,147 | 324,615
| --------- | ---------